Anti-EGFR therapy has found application for casesfrom all three major breast cancer subclasses, respectively, thehormone-sensitive/insensitive group, the ER+/− and HER-2/neu+/− groups, and thebasal-like/triple negative (−) group. This evidence concerns the gene EGFR and breast carcinoma.